FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318580127> ?p ?o ?g. }

• W4318580127 endingPage "i601" @default.
• W4318580127 startingPage "i600" @default.
• W4318580127 abstract "Abstract Background In steroid refractory acute severe ulcerative colitis (ASUC), cyclosporine or infliximab are potential rescue treatments to avoid colectomy. Our objective is to assess the short-term and long-term efficacy and safety of cyclosporine versus infliximab as rescue agents. Methods We performed a retrospective analysis of 121 patients admitted with ASUC to a single gastroenterology centre during 2010-2020. ASUC was defined by the Truelove & Witts criteria. Primary outcome was short-term colectomy-free rate, secondary outcomes were severe adverse events, re-hospitalization or need of treatment with steroids within 2 years due to flare ups and colectomy rate at 2-year follow-up. Results 119 patients initially received intravenous corticosteroids, while 2 patients underwent emergency colectomy on the first day. Sixty-four (53%) were females, median age of all patients was 33 (IQR 27-49) years. 66 (55%) patients responded to intravenous corticosteroids (IVS), while 53 (45%) failed to respond to steroid therapy: 45 (37%) patients received second-line rescue therapy (29 with cyclosporine, 16 with infliximab). Evaluating the short-term efficacy of treatment there was no significant difference between cyclosporine and infliximab: during admission colectomy was performed in 10.3% vs. 12.5% of patients, respectively (p=0.826). In terms of long-term outcomes, the colectomy rate was higher in the infliximab group at 2-year follow-up, although the difference did not reach statistical significance (10.3% vs. 31.2%, p=0.079). The need for oral steroids during follow-up was comparable in both groups (38,5% vs. 50%, p=0.481). Comparing patients who did not undergo colectomy, patients in the infliximab group were more often re-hospitalized due to the need for IVS at 2-year follow-up (7.7% vs. 50%, p=0.002). No severe side effects due to infliximab and cyclosporine were observed. Conclusion In the treatment of steroid refractory ASUC infliximab and cyclosporine were equally effective in short-term period and there was no difference in safety, however cyclosporine treated patients trended to have better long-term outcomes, with significantly rarer re-hospitalization. Additional analysis is needed for other factors that may have contributed to differences in long-term outcomes between the cyclosporine and infliximab groups." @default.
• W4318580127 created "2023-01-31" @default.
• W4318580127 creator A5007236898 @default.
• W4318580127 creator A5035484022 @default.
• W4318580127 creator A5066086405 @default.
• W4318580127 creator A5074502338 @default.
• W4318580127 date "2023-01-30" @default.
• W4318580127 modified "2023-10-16" @default.
• W4318580127 title "P472 Cyclosporine versus infliximab in patients with Acute Severe Ulcerative Colitis: A single-centre retrospective study" @default.
• W4318580127 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0602" @default.
• W4318580127 hasPublicationYear "2023" @default.
• W4318580127 type Work @default.
• W4318580127 citedByCount "0" @default.
• W4318580127 crossrefType "journal-article" @default.
• W4318580127 hasAuthorship W4318580127A5007236898 @default.
• W4318580127 hasAuthorship W4318580127A5035484022 @default.
• W4318580127 hasAuthorship W4318580127A5066086405 @default.
• W4318580127 hasAuthorship W4318580127A5074502338 @default.
• W4318580127 hasBestOaLocation W43185801271 @default.
• W4318580127 hasConcept C126322002 @default.
• W4318580127 hasConcept C141071460 @default.
• W4318580127 hasConcept C167135981 @default.
• W4318580127 hasConcept C197934379 @default.
• W4318580127 hasConcept C2776485726 @default.
• W4318580127 hasConcept C2776667177 @default.
• W4318580127 hasConcept C2777138892 @default.
• W4318580127 hasConcept C2779134260 @default.
• W4318580127 hasConcept C2780479503 @default.
• W4318580127 hasConcept C71924100 @default.
• W4318580127 hasConcept C90924648 @default.
• W4318580127 hasConceptScore W4318580127C126322002 @default.
• W4318580127 hasConceptScore W4318580127C141071460 @default.
• W4318580127 hasConceptScore W4318580127C167135981 @default.
• W4318580127 hasConceptScore W4318580127C197934379 @default.
• W4318580127 hasConceptScore W4318580127C2776485726 @default.
• W4318580127 hasConceptScore W4318580127C2776667177 @default.
• W4318580127 hasConceptScore W4318580127C2777138892 @default.
• W4318580127 hasConceptScore W4318580127C2779134260 @default.
• W4318580127 hasConceptScore W4318580127C2780479503 @default.
• W4318580127 hasConceptScore W4318580127C71924100 @default.
• W4318580127 hasConceptScore W4318580127C90924648 @default.
• W4318580127 hasIssue "Supplement_1" @default.
• W4318580127 hasLocation W43185801271 @default.
• W4318580127 hasOpenAccess W4318580127 @default.
• W4318580127 hasPrimaryLocation W43185801271 @default.
• W4318580127 hasRelatedWork W1481596166 @default.
• W4318580127 hasRelatedWork W1545137436 @default.
• W4318580127 hasRelatedWork W2027117135 @default.
• W4318580127 hasRelatedWork W2063965078 @default.
• W4318580127 hasRelatedWork W2606783118 @default.
• W4318580127 hasRelatedWork W2896429086 @default.
• W4318580127 hasRelatedWork W2944769362 @default.
• W4318580127 hasRelatedWork W3170484542 @default.
• W4318580127 hasRelatedWork W4312067091 @default.
• W4318580127 hasRelatedWork W2168717165 @default.
• W4318580127 hasVolume "17" @default.
• W4318580127 isParatext "false" @default.
• W4318580127 isRetracted "false" @default.
• W4318580127 workType "article" @default.